Icrucumab

Icrucumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetVEGFR-1
Clinical data
Other namesIMC-18F1
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6514H10024N1756O2032S42
Molar mass146796.63 g·mol−1
 NY (what is this?)  (verify)

Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.

Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.